For the year ending 2025-12-31, GRI had $3,201K increase in cash & cash equivalents over the period. -$10,189K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -11,956 |
| Depreciation expense | 4 |
| Stock-based compensation expense | 793 |
| Change in fair value of warrant liability | 0 |
| Change in operating lease right of use assets | 48 |
| Prepaid expenses and other current assets | -251 |
| Accounts payable | 663 |
| Accrued expenses | 59 |
| Operating lease liabilities | -48 |
| Cash used in operating activities | -10,186 |
| Purchase of property and equipment | 3 |
| Cash used in investing activities | -3 |
| Proceeds from issuance of common stock in financing transaction / under atm facility-Through Financing | 13,000 |
| Proceeds from issuance of common stock in financing transaction / under atm facility-At The Market Offering | 2,560 |
| Proceeds from warrant exercise | 0 |
| Payment for fractional shares in connection with reverse stock split | 1 |
| Payment of deferred stock issuance costs | 2,169 |
| Cash provided by financing activities | 13,390 |
| Net increase in cash and cash equivalents | 3,201 |
| Cash and cash equivalents at beginning of period | 5,028 |
| Cash and cash equivalents at end of period | 8,229 |
GRI Bio, Inc. (GRI)
GRI Bio, Inc. (GRI)